SMAD3 Cancer Research Results
SMAD3, SMAD3: Click to Expand ⟱
| Source: |
| Type: |
Deletion or inhibition of Smad3 in the tumour microenvironment suppresses tumour growth, invasion and metastasis in two syngeneic mouse tumour models.
Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development.
|
Scientific Papers found: Click to Expand⟱
P-gp↓, Treatment with berbamine decreased P-glycoprotein (P-gp) expression and down-regulated expression of MDR1 (multi-drug resistance1) and survivin mRNA in K562/A02 cells
MDR1↓,
survivin↓,
NF-kB↓, decrease expression of nuclear factor-B (NF-B), phosphoIB, IKK, and survivin.
TumCP↓, In a chronic myeloid leukemia cell line KU812, berbamine inhibited cell proliferation in a
time- and dose-dependent manner, with IC50 values for treatments of 24, 48, and 72 h at 5.83,
3.43, and 0.75 μg/ml, respectively.
TumCCA↑, Berbamine induced cell cycle arrest at the G1 phase and
also induced apoptosis.
Apoptosis↑,
SMAD3↑, The compound up-regulated transcriptions of Smad3 and p21, and increased protein levels of both total Smad3 and phosphorylated Smad3.
P21↑,
cycD1/CCND1↓, The protein levels of cyclin D1 and c-Myc were reduced.
cMyc↑,
Bcl-2↓, The levels of the anti-apoptotic proteins Bcl-2 and Bcl-xL were decreased, and the level of the pro-apoptotic protein Bax was increased.
Bcl-xL↓,
BAX↑,
CaMKII
↓, The compound has been shown to specifically bind to the ATP-binding pocket of calmodulin kinase (CAMK)II, inhibit its phosphorylation, and trigger apoptosis.
ChemoSen↑, Berbamine also significantly enhanced the activity of anticancer drugs like trichostatin A and celecoxib.
MMP2↓, EBB down-regulated the activities and mRNA levels of matrix
metalloproteinases (MMP) 2 and 9, and up-regulated the mRNA levels of tissue inhibitor of
metalloproteinases (TIMP) 1.
MMP9↓,
TIMP1↑,
cl‑Casp3↑, induction of apoptosis, including activation and cleavage of caspases 3, 8, 9 and PARP.
cl‑Casp9↑,
cl‑Casp8↑,
cl‑PARP↑,
IL6↓, BBD inhibited autocrine IL-6 production, and down-regulated membrane IL-6 receptor (IL-6R) expression.
ROS↑, Production of reactive oxygen species (ROS) was increased by BBMD3 in these cells.
Showing Research Papers: 1 to 1 of 1
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
ROS↑, 1,
Core Metabolism/Glycolysis ⓘ
cMyc↑, 1,
Cell Death ⓘ
Apoptosis↑, 1, BAX↑, 1, Bcl-2↓, 1, Bcl-xL↓, 1, cl‑Casp3↑, 1, cl‑Casp8↑, 1, cl‑Casp9↑, 1, survivin↓, 1,
Kinase & Signal Transduction ⓘ
CaMKII
↓, 1,
DNA Damage & Repair ⓘ
cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
cycD1/CCND1↓, 1, P21↑, 1, TumCCA↑, 1,
Migration ⓘ
MMP2↓, 1, MMP9↓, 1, SMAD3↑, 1, TIMP1↑, 1, TumCP↓, 1,
Barriers & Transport ⓘ
P-gp↓, 1,
Immune & Inflammatory Signaling ⓘ
IL6↓, 1, NF-kB↓, 1,
Drug Metabolism & Resistance ⓘ
ChemoSen↑, 1, MDR1↓, 1,
Clinical Biomarkers ⓘ
IL6↓, 1,
Total Targets: 26
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: SMAD3, SMAD3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:556 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page